Investor Presentation H1 2023

11 Investor presentation First six months of 2023 Novo NordiskⓇ SELECT will add to the clinical evidence of semaglutide to further establish obesity as a serious chronic disease Obesity is a global epidemic affecting more than 764 million people¹ Obesity is associated with >200 possible health complications including cardiovascular disease² Obesity prevalence (%) SELECT adds to clinical evidence underlining obesity as a serious chronic disease STEP & OASIS trials ✓ Demonstrate superior weight loss with semaglutide vs placebo for people with obesity STEP HFPEF trial ✓ Demonstrate superior improvement in KCCQ-CSS vs placebo SELECT CVOT trial SELECT is the largest trial ever completed by Novo Nordisk, including >17,500 participants across more than 800 sites in 41 countries Semaglutide 2.4 mg could become the first and only AOM with a proven CV risk reduction for people with obesity and established CVD <10.0 10.0-19.9 20.0-29.9 ≥30.0 Not applicable 1 World Obesity Atlas 2022 2 Yuen M., Earle R., Kadambi N., et al. A systematic review and evaluation of current evidence reveals 236 Obesity-Associated Disorders (OBAD). Massachusetts General Hospital & George Washington University. [Poster presentation] Note: Obesity is defined as BMI > 30; PWO: People with obesity; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical summary score, CVD: Cardiovascular disease; HFPEF: Heart Failure with preserved ejection fraction; CVOT: Cardiovascular outcomes trial; AOM: Anti-obesity medication; CV: Cardiovascular

View entire presentation